Sign In
Buy LLY
$1,083.23
+18.39 (+1.73%)
At Close: Jun 03, 2026
ImmunoGen (IMGN) Ovarian Cancer Drug BLA Gets Priority Review
01:39pm, Tuesday, 24'th May 2022 Zacks Investment Research
ImmunoGen (IMGN) gets priority review from the FDA for the BLA seeking approval for its lead candidate, mirvetuximab soravtansine, for treating platinum-resistant ovarian cancer.
Eli Lilly and AstraZeneca Are the Lowest Spenders on Dividends, Buybacks
11:03am, Tuesday, 24'th May 2022
Share buybacks and dividends among large drug makers reached a five-year high in 2021 as spending climbed to about $110 billion, according to an analysis by pharma consulting group Evaluate Vantage.
Eli Lilly and Company (LLY) Management Presents at UBS Global Healthcare Conference (Transcript)
10:53am, Tuesday, 24'th May 2022
Eli Lilly and Company (NYSE:LLY ) UBS Global Healthcare Conference May 24, 2022 8:30 AM ET Company Participants Mike Mason - President of Lilly Diabetes Conference Call Participants Colin Bristow - UB
Why This FDA Approval Is a Game Changer for Eli Lilly
10:53am, Tuesday, 24'th May 2022
It could mean billions in revenue for the company.
The Analyst Says 'Impressive Phase 3 Data Highlight Best-In-Class Opportunity' For Concert Pharma
06:44pm, Monday, 23'rd May 2022 Benzinga
Concert Pharmaceuticals Inc (NASDAQ: CNCE) has released highly positive Phase 3 data for their alopecia areata drug CTP-543 from the THRIVE-AA1 trial.
Mizuho says that the efficacy supports its v
What 7 Analyst Ratings Have To Say About Eli Lilly
06:08pm, Monday, 23'rd May 2022 Benzinga
Eli Lilly (NYSE:LLY) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
4
2
0
0
Last 30D
0
1
0
Lilly Announces Webcast to Provide Diabetes and Obesity Portfolio Update at ADA
05:00pm, Monday, 23'rd May 2022
INDIANAPOLIS , May 23, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will host a webcast on Tuesday, June 7, 2022 to discuss the company's diabetes and obesity portfolio and its presentations
Lilly's (LLY) Olumiant Gets CHMP Nod for Alopecia Areata
03:33pm, Monday, 23'rd May 2022 Zacks Investment Research
The CHMP gives a positive opinion and recommends approval of Lilly's (LLY) Olumiant to treat adults with severe alopecia areata.
Lilly's (LLY) Olumiant Gets CHMP Nod for Alopecia Areata
12:48pm, Monday, 23'rd May 2022
The CHMP gives a positive opinion and recommends approval of Lilly's (LLY) Olumiant to treat adults with severe alopecia areata.
CHMP Backs Approval of Lilly/Incyte's Olumiant For Patchy Hair Loss
03:08pm, Friday, 20'th May 2022
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Eli Lilly And Co (NYSE: LLY) and Incyte Corporation's (NASDAQ: INCY)
Eli Lilly Gets Positive Opinion for Olumiant in Europe. The Stock Rises.
02:06pm, Friday, 20'th May 2022
The opinion marks the first step toward European regulatory approval of the oral JAK inhibitor for the treatment of adults with severe alopecia areata.
3 Health Care Stocks To Watch Right Now
12:30pm, Friday, 20'th May 2022
Could these health care stocks be safe bets in the stock market today?
Why Eli Lilly Shares Are Rising Today
10:54am, Friday, 20'th May 2022
Eli Lilly And Co (NYSE: LLY) shares are trading higher by 3.58% at $296.48 after the company announced the CHMP has issued a positive opinion for OLUMIANT for the treatment of adults with severe alope
4 Large Drug Stocks to Watch as the Industry Recovers
11:17am, Thursday, 19'th May 2022
Drug/biotech companies are likely to see significant advances in innovation in 2022. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Glaxo (GSK) are wor
Why Eli Lilly Stock Climbed Today
02:20pm, Monday, 16'th May 2022
The biotech's new diabetes drug could be a game changer.
